Skip to main content
. Author manuscript; available in PMC: 2021 Oct 15.
Published in final edited form as: Arch Biochem Biophys. 2020 Aug 18;692:108546. doi: 10.1016/j.abb.2020.108546

Figure 6: EGCG enhances the effect of gemcitabine on the ERK pathway inhibition in pancreatic cancer.

Figure 6:

A: Immunoblots for phosphorylated/total ERK and phosphorylated and total ERK in whole cell protein extracts from Panc-1 and MIA PaCa-2 cells treated with EGCG (E), gemcitabine (G), or both (G + E) for 24 h. Loading control: β-Actin. Bands were quantified and results expressed as the p-ERK/ERK ratio, normalized to control. * p<0.05, ** p<0.01 vs. control. B: Immunohistochemistry analysis performed on mouse pancreatic tumor xenograft samples. p-ERK immunostainings were performed on tumor sections and photographs were taken at 20x magnification. Representative images are shown. Results were expressed as percent of p-ERK(+) cells ± SD per 20x field. *Significant compared to control group; p<0.05.